More importantly, clinical research data have not observed that DPP1 inhibitor treatment significantly increases serious infection risks, supporting the conclusion that DPP1 inhibition has relatively limited impact on host defense functions within therapeutic dose ranges ( Looking toward future research directions, attention should focus on long-term safety assessment of DPP1 inhibitors, biomarker development, optimal dosage determination, and combination treatment strategies
Patients receiving tirzepatide and sermorelin together require enhanced monitoring protocols beyond standard care for either medication alone, given the absence of established safety data for this combination
Maternal periconceptional folic acid intake and risk of autism spectrum disorders and developmental delay in the CHARGE (CHildhood Autism Risks from Genetics and Environment) case-control study
Astorg has offices in London, Paris, New York, Frankfurt, Milan, and Luxembourg
JAMA 326 (1), 6576
